香港股市 將在 6 小時 11 分鐘 開市

Verve Therapeutics, Inc. (VERV)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
7.49+0.41 (+5.86%)
市場開市。 截至 03:18PM EDT。

Verve Therapeutics, Inc.

201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com

版塊Healthcare
行業Biotechnology
全職員工255

高階主管

名稱頭銜支付行使價出生年份
Dr. Sekar Kathiresan M.D.Co-Founder, CEO & Director973.25k1972
Ms. Allison DorvalCFO & Principal Accounting Officer711.76k1976
Mr. Andrew D. Ashe J.D.President, COO & General Counsel703.85k1967
Dr. Kiran Musunuru M.D., M.P.H., Ph.D.Co-Founder
Dr. J. Keith Joung M.D., Ph.D.Co-Founder
Dr. Anthony Philippakis M.D., Ph.D.Co-Founder & Scientific Advisory Board Member7.97k
Dr. Barry S. Ticho FACC, M.D., Ph.D.Co-Founder1961
Mr. Issi Rozen M.B.A.Co-Founder & Strategic Advisor
Dr. Troy Lister Ph.D.Chief Scientific Officer
Ms. Joan Nickerson M.B.A.Chief Administrative Officer1969
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年7月1日 止,Verve Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:2;董事會:8;股東權利:8;現金賠償:8。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。